Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 2 of 630 for:    "Crohns disease"

High-dose Cyclophosphamide for Severe Refractory Crohn Disease

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified May 2013 by Johns Hopkins University
Information provided by (Responsible Party):
Mark Lazarev, MD, Johns Hopkins University Identifier:
First received: April 17, 2013
Last updated: May 18, 2013
Last verified: May 2013

This research is being done to see if people with Crohn's disease who receive high-dose cyclophosphamide have an improvement of their disease, how long the benefit may last, and how safe cyclophosphamide is. This study is for patient with medically refractory disease that is not easily amenable to surgery.

Cyclophosphamide is an FDA-approved chemotherapy medication that is also frequently used to treat autoimmune illness; use of cyclophosphamide for autoimmune disease is not approved by the FDA. An autoimmune illness is when the immune system mistakenly attacks self, targeting the cells, tissues, and organs of a person's own body. There are many different autoimmune diseases and they can each affect the body is different ways. Crohn's disease is an autoimmune disease that primarily affects the small and large intestines. High dose-cyclophosphamide has been successfully used to treat Crohn's, primarily as part of a conditioning regimen for autologous stem cell transplantation. However, this therapy is limited in Crohn's because of it's serious infectious risks. This current study involves using high-dose cyclophosphamide without need for stem cell transplantation. This appears to be a safer approach in other autoimmune illnesses that have been studied.

Condition Intervention Phase
Crohn's Disease
Crohn Disease
Drug: High-dose Cyclophosphamide
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: High-dose Cyclophosphamide for Severe Refractory Crohn Disease

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Crohn's Symptoms: Drop in Crohn's Disease Activity Index (CDAI) of 100 Points [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    For Crohn's symptoms, response is defined as a drop in the CDAI of 100 points. Remission is defined as a CDAI of < 150.

  • Endoscopic Outcomes: Absence of Ulcers on Colonoscopy [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    For endoscopic outcomes, response is defined as absence of ulcers on colonoscopy (in patients who had ulcers at the baseline colonoscopy).

Secondary Outcome Measures:
  • High-dose Cyclophosphamide (HDC)-Induced Remission [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    To determine if HDC therapy can induce and maintain a clinical remission at 12 and 52 weeks.

  • HDC-Induced Mucosal Healing [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    To determine if HDC therapy can induce sustained mucosal healing at 12 and 52 weeks.

  • Molecular Mechanisms of High-dose Cyclophosphamide (HiCy) Therapy [ Time Frame: 3 Years ] [ Designated as safety issue: No ]
    To investigate the molecular mechanisms by which HiCy therapy works by analyzing the effects of HiCy on the levels of serum cytokines (using multiplex ELISA), and correlate the data with clinical activity and treatment response.

Estimated Enrollment: 10
Study Start Date: May 2013
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: High-dose Cyclophosphamide
High-dose Cyclophosphamide
Drug: High-dose Cyclophosphamide
Other Names:
  • Endoxan®
  • Cytoxan®
  • CTX
  • Neosar®
  • Procytox®
  • Revimmune™


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 years of age, males and females will be eligible
  • Moderate to severe Crohn's Disease (CD) with CDAI > 220, in addition to evidence of ulceration on ileocolonoscopy or active disease on small bowel imaging
  • Disease progression (primary or secondary non-responder, or reaction to) to at least one anti-tumor necrosis factor (TNF) agent (infliximab, adalimumab, certolizumab pegol), and additionally had disease progression despite one of the following immunosuppressant drugs: azathioprine, 6-mercaptopurine, methotrexate, cyclosporine or natalizumab.
  • Willingness to participate in a clinical trial

Exclusion Criteria:

  • Pregnant or nursing women
  • Sexually active men and women who do not agree to use effective means of birth control during treatment period
  • Evidence of primarily fibrostenosing disease without active inflammatory disease on disease staging
  • Co-morbid conditions including cardiac disease with an ejection fraction of < 45%, chronic renal failure with serum creatinine > 2.0, liver disease with total bilirubin > 2.0, (excluding hyperbilirubinemia secondary to Gilbert's disease) or transaminitis > 3x upper limit of normal.
  • History of serious allergic reaction to cyclophosphamide
  • History of malignancy in the last 5 years (excluding non-melanomatous skin cancers)
  • Patients who are pre-terminal
  • Toxic megacolon
  • Active infection
  • White blood cell count < 3000 cells/ul, platelets < 100K / ul, hemoglobin < 10.0 g/dL
  • Any use of thiopurines, methotrexate or anti-TNF agents in the previous four weeks prior to treatment
  • Patients with an ileostomy or colostomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01836289

Contact: Mark G. lazarev, MD 410.502-3147

United States, Maryland
Johns Hopkins Medical Institutions Not yet recruiting
Baltimore, Maryland, United States, 21205
Contact: Mark G. lazarev, MD    410-502-3147   
Sponsors and Collaborators
Johns Hopkins University
Principal Investigator: Mark G. Lazarev, MD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Mark Lazarev, MD, Assistant Professor of Medicine, Johns Hopkins University Identifier: NCT01836289     History of Changes
Other Study ID Numbers: NA_00052668
Study First Received: April 17, 2013
Last Updated: May 18, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014